AbbVie bets $370M on pivotal eye disease gene therapy, puts up $1.4B in biobucks | Fierce Biotech

August 26, 2022:

AbbVie bets $370M on pivotal eye disease gene therapy, puts up $1.4B in biobucks | Fierce Biotech